JP2016504363A5 - - Google Patents

Download PDF

Info

Publication number
JP2016504363A5
JP2016504363A5 JP2015550682A JP2015550682A JP2016504363A5 JP 2016504363 A5 JP2016504363 A5 JP 2016504363A5 JP 2015550682 A JP2015550682 A JP 2015550682A JP 2015550682 A JP2015550682 A JP 2015550682A JP 2016504363 A5 JP2016504363 A5 JP 2016504363A5
Authority
JP
Japan
Prior art keywords
triazolo
amine
methoxy
quinazoline
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015550682A
Other languages
English (en)
Japanese (ja)
Other versions
JP6306049B2 (ja
JP2016504363A (ja
Filing date
Publication date
Priority claimed from PCT/CN2012/087865 external-priority patent/WO2014101120A1/en
Application filed filed Critical
Publication of JP2016504363A publication Critical patent/JP2016504363A/ja
Publication of JP2016504363A5 publication Critical patent/JP2016504363A5/ja
Application granted granted Critical
Publication of JP6306049B2 publication Critical patent/JP6306049B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015550682A 2012-12-28 2013-12-20 A2aアンタゴニスト特性を有するヘテロビシクロ−置換−[1,2,4]トリアゾロ[1,5−c]キナゾリン−5−アミン化合物 Expired - Fee Related JP6306049B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/CN2012/087865 WO2014101120A1 (en) 2012-12-28 2012-12-28 Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
CNPCT/CN2012/087865 2012-12-28
PCT/CN2013/076853 WO2014101373A1 (en) 2012-12-28 2013-06-06 Heterobicyclo-substituted-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds for treatment of central nervous system disorder
CNPCT/CN2013/076853 2013-06-06
PCT/US2013/076781 WO2014105666A1 (en) 2012-12-28 2013-12-20 Heterobicyclo-substituted-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties

Publications (3)

Publication Number Publication Date
JP2016504363A JP2016504363A (ja) 2016-02-12
JP2016504363A5 true JP2016504363A5 (show.php) 2017-01-12
JP6306049B2 JP6306049B2 (ja) 2018-04-04

Family

ID=51019745

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015550682A Expired - Fee Related JP6306049B2 (ja) 2012-12-28 2013-12-20 A2aアンタゴニスト特性を有するヘテロビシクロ−置換−[1,2,4]トリアゾロ[1,5−c]キナゾリン−5−アミン化合物

Country Status (22)

Country Link
US (2) US9708347B2 (show.php)
EP (1) EP2945632B1 (show.php)
JP (1) JP6306049B2 (show.php)
KR (1) KR102165113B1 (show.php)
AU (1) AU2013370977B2 (show.php)
BR (1) BR112015015468B8 (show.php)
CA (1) CA2896056C (show.php)
CY (1) CY1120258T1 (show.php)
DK (1) DK2945632T3 (show.php)
ES (1) ES2667477T3 (show.php)
HR (1) HRP20180678T1 (show.php)
HU (1) HUE037950T2 (show.php)
LT (1) LT2945632T (show.php)
ME (1) ME03034B (show.php)
MX (1) MX370017B (show.php)
NO (1) NO2945632T3 (show.php)
PL (1) PL2945632T3 (show.php)
PT (1) PT2945632T (show.php)
RS (1) RS57162B1 (show.php)
RU (2) RU2671628C2 (show.php)
SI (1) SI2945632T1 (show.php)
WO (3) WO2014101120A1 (show.php)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3253390B1 (en) * 2015-02-06 2022-04-13 Merck Sharp & Dohme Corp. Aminoquinazoline compounds as a2a antagonist
US10688082B2 (en) 2015-06-11 2020-06-23 Merck Sharp & Dohme Corp. Aminopyrazine compounds with A2A antagonist properties
WO2017008205A1 (en) * 2015-07-10 2017-01-19 Merck Sharp & Dohme Corp. Substituted aminoquinazoline compounds as a2a antagonist
US10821106B2 (en) 2015-08-21 2020-11-03 Srx Cardio, Llc Composition and methods of use of novel phenylalanine small organic compounds to directly modulate PCSK9 protein activity
EP3337564A4 (en) * 2015-08-21 2019-01-23 Portola Pharmaceuticals, Inc. COMPOSITION AND METHOD FOR THE USE OF TETRAHYDROISOCHINOLINE SMALL MOLECULES FOR THE BINDING AND MODULATION OF PCSK9 PROTEIN ACTIVITY
WO2017034997A1 (en) 2015-08-21 2017-03-02 Portola Pharmaceuticals, Inc. Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (pcsk9) modulators and their use
WO2017107089A1 (en) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
WO2017107087A1 (en) * 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 6, 7-dihydro-5h-pyrrolo [3, 4-b] pyridin-5-oneallosteric modulators of the m4 muscarinic acetylcholine receptor
US10329289B2 (en) 2015-12-23 2019-06-25 Merck Sharp & Dohme Corp. 6,7-dihydro-5H-pyrrolo[3,4-B]pyridin-5-one allosteric modulators of the M4 muscarinic acetylcholine receptor
US20190119236A1 (en) 2016-02-23 2019-04-25 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
WO2018112843A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2018112842A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor
US11014904B2 (en) 2017-01-13 2021-05-25 Jiangsu Hengrui Medicine Co., Ltd. 1,2,4-triazine-3-amine derivative, preparation method therefor, and use thereof in medicine
SG11201907909TA (en) 2017-02-27 2019-09-27 Betta Pharmaceuticals Co Ltd Fgfr inhibitor and application thereof
UA125592C2 (uk) 2017-03-16 2022-04-27 Джянгсу Хенгруй Медісін Ко., Лтд. ПОХІДНА ГЕТЕРОАРИЛ[4,3-c]ПІРИМІДИН-5-АМІНУ, СПОСІБ ЇЇ ОТРИМАННЯ ТА ЇЇ МЕДИЧНІ ЗАСТОСУВАННЯ
ES2927086T3 (es) 2017-09-28 2022-11-02 Cstone Pharmaceuticals Suzhou Co Ltd Derivado de anillo condensado como inhibidor del receptor A2A
EP3723754A4 (en) 2017-12-13 2021-05-19 Merck Sharp & Dohme Corp. IMIDAZO [1,2-C] QUINAZOLINE-5-AMINE COMPOUNDS WITH PROPERTIES OF A2A ANTAGONIST
US20210032253A1 (en) 2018-02-06 2021-02-04 Jiangsu Hengrui Medicine Co., Ltd. Pyrazolo[1,5-a][1,3,5]triazine-2-amine derivative, preparation method therefor and medical use thereof
EP3883576B1 (en) 2018-11-20 2025-12-17 Merck Sharp & Dohme LLC Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
MA55142A (fr) 2018-11-20 2022-02-23 Merck Sharp & Dohme Amino-triazolopyrimidine et amino-triazolopyrazine substitués antagoniste du récepteur de l'adénosine, compositions pharmaceutiques et leur utilisation
CA3120331A1 (en) 2018-11-30 2020-06-04 Merck Sharp & Dohme Corp. 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use
CN113329791A (zh) 2018-11-30 2021-08-31 默沙东公司 作为腺苷受体拮抗剂的9-取代的氨基三唑并喹唑啉衍生物、药物组合物及其用途
BR112021012685A2 (pt) 2019-01-11 2021-12-28 Omeros Corp Métodos para tratar câncer, para aumentar o nível de citocinas th1 nas células mononucleares de sangue periférico humanas, para realçar uma resposta imune antitumoral e para estimular e/ou amplificar uma resposta imune em um sujeito mamífero sofrendo de ou em risco de desenvolver câncer ou metástase de câncer, e, composição farmacêutica
AR117844A1 (es) 2019-01-22 2021-09-01 Merck Patent Gmbh Derivados de tiazolopiridina como antagonistas del receptor de adenosina
AU2019437315B2 (en) 2019-03-26 2022-10-06 Novel Pharma Inc. Long-acting fatty acid-binding GnRH derivative and pharmaceutical composition comprising same
MX2022009524A (es) 2020-02-07 2023-01-11 Gasherbrum Bio Inc Agonistas heterociclicos de glp-1.
EP4185296A4 (en) * 2020-07-24 2025-03-05 Merck Sharp & Dohme LLC DUAL ADENOSINE A2A RECEPTOR AND A2B RECEPTOR ANTAGONISTS FOR IMMUNO-ONCOLOGY
EP4185297A4 (en) * 2020-07-24 2024-08-28 Merck Sharp & Dohme LLC Adenosine a2a and a2b receptor dual antagonists for immuno-oncology
CN112159411A (zh) * 2020-10-15 2021-01-01 南京工业大学 一种三氟甲基取代嘧啶并[1,3]二氮杂*化合物及其制备方法
US12115154B2 (en) 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
WO2023201267A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
WO2024169952A1 (en) 2023-02-16 2024-08-22 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713383A (en) * 1984-10-01 1987-12-15 Ciba-Geigy Corporation Triazoloquinazoline compounds, and their methods of preparation, pharmaceutical compositions, and uses
EP0181282A1 (de) * 1984-10-01 1986-05-14 Ciba-Geigy Ag Triazolochinazolinverbindungen
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
WO1995003806A1 (en) * 1993-07-27 1995-02-09 Kyowa Hakko Kogyo Co., Ltd. Remedy for parkinson's disease
US5736564A (en) * 1994-06-20 1998-04-07 Smithkline Beecham Corporation Endothelin receptor antagonists
US5571775A (en) * 1994-07-11 1996-11-05 Dowelanco N-aryl[1,2,4]triazolo[1,5-a]pyridine-2-sulfonamide herbicides
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
US5929106A (en) * 1997-10-27 1999-07-27 Smithkline Beecham Corporation Endothelin receptor antagonists
WO2001092264A1 (en) 2000-05-26 2001-12-06 Schering Corporation Adenosine a2a receptor antagonists
WO2001099264A1 (en) * 2000-06-20 2001-12-27 Rees, Alexander, Ellison Electrical drive line
US6358964B1 (en) * 2000-07-26 2002-03-19 King Pharmaceuticals Research And Development, Inc. Adenosine, A3 receptor modulators
GB0100624D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
EP1527074A1 (en) * 2002-07-25 2005-05-04 Pharmacia Italia S.p.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
TWI331036B (en) * 2002-12-19 2010-10-01 Schering Corp Adenosine a2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
ATE418555T1 (de) * 2003-04-09 2009-01-15 Biogen Idec Inc A2a-adenosinrezeptorantagonisten
CA2522813C (en) * 2003-04-23 2009-09-08 Schering Corporation 2-alkynyl-and 2-alkenyl-pyrazolo-¬4,3-e|-1,2,4-triazolo-¬1,5-c|-pyrimidine adenosine a2a receptor antagonists
PE20070521A1 (es) * 2005-09-23 2007-07-13 Schering Corp 7-[2-[4-(6-FLUORO-3-METIL-1,2-BENCISOXAZOL-5-IL)-1-PIPERAZINIL]ETIL]-2-(1-PROPINIL)-7H-PIRAZOL-[4,3-E]-[1,2,4]-TRIAZOL-[1,5-C]-PIRIMIDIN-5-AMINA COMO ANTAGONISTA DEL RECEPTOR DE ADENOSINA A2a
JP2010509189A (ja) 2006-06-26 2010-03-25 シェーリング コーポレイション アデノシンA2aレセプターアンタゴニスト
US20090062253A1 (en) 2007-08-31 2009-03-05 Kalypsys, Inc. Heterocyclodiazepine cannabinoid receptor modulators for treatment of disease
EP2210891A1 (en) * 2009-01-26 2010-07-28 Domain Therapeutics New adenosine receptor ligands and uses thereof
WO2011060207A1 (en) * 2009-11-16 2011-05-19 Schering Corporation FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY
WO2012135084A1 (en) 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. METABOLITES OF 2-(FURAN-2-YL)-7-(2-(4-(4-(2-METHOXYETHOXY)PHENYL)PIPERAZIN-1-YL)ETHYL)-7H-PYRAZOLO[4,3-e][1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-5-AMINE AND THEIR UTILITY AS ADENOSINE A2a RECEPTOR ANTAGONISTS
WO2014101113A1 (en) 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Piperazine-substituted 7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties

Similar Documents

Publication Publication Date Title
JP2016504363A5 (show.php)
RU2015131148A (ru) СОЕДИНЕНИЯ, ГЕТЕРОБИЦИКЛО-ЗАМЕЩЕННЫЕ-[1, 2, 4]ТРИАЗОЛО[1, 5c]ХИНАЗОЛИН-5-АМИНА, ОБЛАДАЮЩИЕ СВОЙСТВАМИ А2А АНТАГОНИСТОВ
IL275522B1 (en) Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors
JP2011500774A5 (show.php)
RU2020133727A (ru) Ингибиторы shp2 и их применение
RU2443706C2 (ru) Фармацевтические соединения
CN117651700A (zh) 2-氨基苯并噻唑化合物及使用方法
WO2025049746A1 (en) Compositions comprising werner syndrome helicase inhibitors and methods of using the same
JP2021503004A5 (show.php)
JP2021518395A5 (show.php)
JP2020522570A5 (show.php)
HRP20120105T1 (hr) Aminoheterociklički spojevi
JP2015504057A5 (show.php)
WO2011035518A1 (zh) 嘧啶衍生物和类似物及其制备方法和用途
RU2012136907A (ru) Модуляторы гамма-секретазы
RU2016111675A (ru) Соединения биарилацетамида и способы их применения
JP2013500975A5 (show.php)
JP2017503867A5 (show.php)
JP2014506929A5 (show.php)
JP2012527483A5 (show.php)
RU2018112230A (ru) Бициклические соединения в качестве ингибиторов atx
JP2017518326A5 (show.php)
ES2637816T3 (es) Derivados de imidazo-triazina como inhibidores de PDE10
JPWO2020065613A5 (show.php)
JPWO2020065614A5 (show.php)